The Effect of Sono-guided Injection With Platelet Rich Plasma for Carpal Tunnel Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Carpal Tunnel Syndrome
- Sponsor
- Tri-Service General Hospital
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Change from baseline of pain on 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks after treatment.
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders. Although few studies have showed beneficial effect of PRP for regeneration of peripheral neuropathy in animal study, the associated study in human is rare.
Detailed Description
The platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders. Although few studies have showed beneficial effect of PRP for regeneration of peripheral neuropathy in animal study, the associated study in human is rare. We performe a prospective study to investigate the effect of PRP in patients with carpal tunnel syndrome. Patients with carpal tunnel syndrome (CTS) were randomized into intervention and control group. Participants in intervention group received sono-guided injection with 3cc PRP and control group received night splint. The evaluation was performed pretreatment as well as on the 1st, 4th, 8th, 12th, 16th and 24 week after the treatment.
Investigators
Yung-Tsan Wu
Attending physician
Tri-Service General Hospital
Eligibility Criteria
Inclusion Criteria
- •Age between 20-80 year-old.
- •Typical symptoms and signs of CTS, such as positive Tinel's sign or Phalen's test, numbness/tingling in at least two of the first, second, or third digits, and in whom the diagnosis was confirmed using an electrophysiological study.
Exclusion Criteria
- •Coagulopathy
- •Inflammation status
- •Patients who had conditions mimicking CTS, such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome or who had previously undergone wrist surgery or steroid injection for CTS.
Outcomes
Primary Outcomes
Change from baseline of pain on 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks after treatment.
Time Frame: 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks after treatment.
Visual analog scale (VAS)
Secondary Outcomes
- Change from baseline of severity of symptoms and functional status 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks(Pre-treatment, 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks after treatment.)
- Change from baseline of cross-sectional area in median nerve on 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks(Pre-treatment, 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks after treatment.)
- Change from baseline of electrophysiological study on 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks(Pre-treatment, 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks after treatment.)
- Change from baseline in finger pinch on 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks(Pre-treatment, 1st, 2nd, 4th, 8th, 12th, 16th and 24th weeks after treatment.)